老年急性心肌梗死患者应用替格瑞洛的安全性和有效性评价

目的评价替格瑞洛治疗老年患者急性心肌梗死的安全性和有效性。方法选取2013年12月~2015年5月>60岁的急性心肌梗死患者,按照随机数字表法分为氯吡格雷组和替格瑞洛组,随访两组患者的终点事件,比较氯吡格雷和替格瑞洛的安全性和有效性。结果替格瑞洛治疗组再发心梗和心血管死亡的发生率明显低于氯吡格雷治疗组(P<0.05),而两组出血发生率差异无统计学意义(P>0.05)。结论与应用氯吡格雷相比,老年急性心梗患者应用替格瑞洛再发心肌梗死和心血管死亡的发生率下降,出血发生率未增加,替格瑞洛治疗老年患者急性心梗具有良好的安全性和有效性。

Efficacy and safety of ticagrelor in elderly with acute myocardial infarction

Objective To evaluate the efficacy and safety of ticagrelor in elderly people with acute myocardial infarction. Methods In total, 180 elderly people 60 years and older with acute myocardial infarction were included; the participants were assigned randomly and evenly to take ticagrelor or clopidogrel. The treatment course lasted for 12 months. Results Median age was 72 (61-84) years,and 98 men were included. The incidence of recurrent myocardial infarction and cardiovascular death were significantly lower in the elderly participants taking ticagrelor compared to those taking clopidogrel (all P < 0.05). There was no difference in the incidence of bleeding between the two groups (P > 0.05). Conclusion The incidence of recurrent myocardial infarction and cardiovascular death were lower and the incidence of bleeding was similar in elderly people taking ticagrelor compared to those taking clopidogrel,showing the efficacy and safety of ticagrelor in elderly people with acute myocardial infarction.